Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer

NCT01418222 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01418222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01418222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2011
Completion date
March 18, 2013
Enrollment
194 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer